|
|
|
| Predictive efficacy of serum macrophage inflammatory protein-3α com-bined with receptor interacting protein kinase 3 levels for the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure |
| LI Pinqing1 YAO Yu2 DING Kai1 XUE Chenqi1 QIU Jie1 |
1.The First Department of Tumor and Vascular Disease Intervention, Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine the Second Hospital of Nanjing, Jiangsu Province, Nanjing 210003, China;
2.the Second Department of Tumor and Vascular Disease Intervention, Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine the Second Hospital of Nanjing, Jiangsu Province, Nanjing 210003, China |
|
|
|
|
Abstract Objective To investigate the predictive efficacy of serum macrophage inflammatory protein-3α (MIP-3α) combined with receptor interacting protein kinase 3 (RIPK3) on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Methods A total of 246 patients with HBV-ACLF admitted to the Second Hospital of Nanjing from February 2021 to July 2022 were selected. The serum levels of MIP-3α and RIPK3 were detected. According to the survival situation within 30 days, the patients were divided into the death group (73 cases) and the survival group (173 cases). The clinical data of the two groups were compared, and the factors affecting the short-term prognosis of patients with HBV-ACLF and the predictive value of MIP-3α and RIPK3 for the prognosis of patients with HBV-ACLF were analyzed. Results The serum albumin level in the death group was lower than that in the survival group, the international normalized ratio, model for end-stage liver disease (MELD) score, the proportion of complicated encephalopathy, and the serum total bilirubin, MIP-3α, and RIPK3 levels were higher than those in the survival group (P＜0.05). MELD score (OR=3.347, 95%CI: 1.844-6.073), and serum MIP-3α (OR=2.079, 95%CI: 1.307-3.309), RIPK3 (OR=2.004, 95%CI: 1.312-3.060) were influential factors for short-term prognosis of HBV-ACLF patients (P＜0.05). MELD score combined with serum MIP-3α and RIPK3 predicted the prognosis of HBV-ACLF patients with higher area under the receiver operator charcateristic curve than the area under the curve predicted by the three alone (P＜0.05). Conclusion Serum MIP-3α and RIPK3 levels are elevated in HBV-ACLF patients, and are associated with short-term death. Combined analysis of MELD score and serum MIP-3α, RIPK3 helped to indicate the prognosis of patients.
|
|
|
|
|
|
[1] Chen L，Dai J，Xie Q，et al. Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure [J]. Gut Liver，2022，16（3）：456-464.
[2] Wang K，Zhang Z，Mo ZS，et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure [J]. Gut Microbes，2021，13（1）：1-15.
[3] Kadomoto S，Izumi K，Mizokami A. The CCL20-CCR6 Axis in Cancer Progression [J]. Int J Mol Sci，2020，21（15）：5186.
[4] 符晓，朱巍.巨噬细胞炎性蛋白1α、碱性成纤维细胞生长因子对肺癌脑转移临床诊疗的意义[J].癌症进展，2021， 19（8）：795-797，863.
[5] Liu S，Joshi K，Denning MF，et al. RIPK3 signaling and its role in the pathogenesis of cancers [J]. Cell Mol Life Sci，2021，78（23）：7199-7217.
[6] 夏思颖，杨亚楠，闫香珍，等.受体相互作用蛋白激酶1在小鼠实验性牙周炎模型中的作用[J].实用口腔医学杂志，2021，37（5）：596-600.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南（2018年版）[J].中华临床感染病杂志，2018，11（6）：E001.
[8] Wiesner R，Edwards E，Freeman R，et al. Model for end-stage liver disease（MELD）and allocation of donor livers [J]. Gastroenterology，2003.124（1）：91-96.
[9] Ma S，Xie Z，Zhang L，et al. Identification of a Potential miRNA- mRNA Regulatory Network Associated With the Prognosis of HBV-ACLF [J]. Front Mol Biosci，2021，8：657631.
[10] 韩成美，任运华，丁雷.COSSH-ACLF评分联合血清白细胞介素-37水平对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值[J].实用医学杂志，2021， 37（4）：472-476.
[11] 张蕾，贺建勋，范雪松，等.抗凝血酶Ⅲ活性联合CLIF- C OFs评分对HBV相关慢加急性肝衰竭患者预后的评估价值[J].疑难病杂志，2022，21（1）：36-40，45.
[12] Zhang F，Sun L，Lafferty MK，et al. Decreased MIP-3α Production from Antigen-Activated PBMCs in Symptomatic HIV-Infected Subjects [J]. Pathogens，2021，11（1）：7.
[13] 逯玲.急性呼吸窘迫综合征病人血清可溶性髓样细胞触发受体1、巨噬细胞炎症蛋白-1α的表达[J].安徽医药，2021，25（7）：1442-1446.
[14] Aziz N，Detels R，Chang LC，et al. Macrophage Inflammatory Protein-3 Alpha （MIP-3α）/CCL20 in HIV-1-Infected Individuals [J]. J AIDS Clin Res，2016，7（7）：587.
[15] Yang CY，Kuo YH，Chen M，et al. Pleural cytokines MIF and MIP-3α as novel biomarkers for complicated parapneumonic effusions and empyema [J]. Sci Rep，2021，11（1）：1763.
[16] Sosa-Jurado F，Sánchez-Reza L，Mendoza-Torres Má，et al. Serum Th17 and TNF-α distinguish between patients with occult hepatitis B infection，chronic hepatitis B infection and healthy individuals [J]. Eur Cytokine Netw，2021，32（2）：23-30.
[17] Zhang X，Zhang Y，Zhou P，et al. Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients [J]. Emerg Microbes Infect，2022，11（1）：1586-1601.
[18] Park HH，Kim HR，Park SY，et al. RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment [J]. Mol Cancer，2021，20（1）：107.
[19] Zhang T，Zhang Y，Cui M，et al. CaMKII is a RIP3 substrate mediating ischemia-and oxidative stress-induced myocardial necroptosis [J]. Nat Med，2016，22（2）：175-182.
[20] Sureshbabu A，Patino E，Ma KC，et al. RIPK3 promotes sep- sis-induced acute kidney injury via mitochondrial dysfunction [J]. JCI Insight，2018，3（11）：e98411.
[21] Martin-Sanchez D，Guerrero-Mauvecin J，Fontecha-Barriuso M，et al. Bone Marrow-Derived RIPK3 Mediates Kidney Inflammation in Acute Kidney Injury [J]. J Am Soc Nep- hrol，2022，33（2）：357-373.
[22] Afonso MB，Rodrigues PM，Mateus-Pinheiro M，et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease [J]. Gut. 2021，70（12）：2359-2372.
[23] Shojaie L，Iorga A，Dara L. Cell Death in Liver Diseases：A Review [J]. Int J Mol Sci，2020，21（24）：9682.
[24] Günther C，He GW，Kremer AE，et al. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis [J]. J Clin Invest，2016， 126（11）：4346-4360.
[25] 高心怡，陈丽，甘建和.MELD评分联合血小板/白细胞比值对HBV相关慢加急性肝衰竭患者预后的预测价值[J].临床肝胆病杂志，2021，37（5）：1070-1074.
[26] 柳梅，亓敏，丁雷，等.血浆髓样细胞触发受体2联合终末期肝病模型评分对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的预测价值[J].实用医学杂志，2022， 38（4）：473-478. |
|
|
|
